FDA staff: Calcitonin salmon may carry cancer risk

03/3/2013 | Reuters

A link between osteoporosis treatments containing calcitonin salmon and cancer risk is possible, according to briefing documents from FDA staff reviewers. The reviewers raised questions about the drugs' usefulness in preventing bone breaks due to osteoporosis in postmenopausal women, the reviewers said. An FDA panel is set to discuss the products on Tuesday.

View Full Article in:

Reuters

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Senior Manager, Clinical Affairs - Advanced Technology
Edwards Lifesciences
Irvine, CA
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA